China National Pharmaceutical Group

From Wikipedia, the free encyclopedia
"Sinopharm" redirects here. For other uses, see Sinopharm (disambiguation).

Coordinates: 39°58′29″N 116°20′24″E / 39.9747°N 116.3401°E / 39.9747; 116.3401

China National Pharmaceutical Group
Sinopharm
Typestate-owned enterprise
FoundedNovember 26, 1998
Headquarters20 Zhichun Road, Haidian District,
Beijing
,
China
Area served
China, exported worldwide
Key people
Liu Jingzhen (Chairman & Party Committee Secretary)[1][2]
RevenueIncrease CN¥247.110 billion (2014)
Increase CN¥8.758 billion (2014)
Increase CN¥2.705 billion (2014)
Total assetsIncrease CN¥199.192 billion (2014)
Total equityIncrease CN¥31.944 billion (2014)
OwnerChinese central government (100%)
ParentSASAC of the State Council
Subsidiaries
  • Sinopharm Industrial Investment (51%)
  • → Sinopharm Group (56.79%)
  • (37.59%)
  • (41.62%)
  • China National Biotec Group (95%)
  • → (53.30%)
Chinese name
Simplified Chinese中国医药集团总公司
Traditional Chinese中國醫藥集團總公司
short Chinese name
Simplified Chinese国药集团
Traditional Chinese國藥集團
Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards[3]

China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical),  [zh] (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.).[4] (SSE: 600420, via a wholly owned research institute based in Shanghai) and (SSE: 600161, via China National Biotec Group).

China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.[5]

Sinopharm was ranked 205th in 2016 Fortune Global 500 list.[6]

History[]

China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) was founded on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).

Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective DPT vaccines in November 2017.[7]

COVID-19 vaccine[]

Main article: Sinopharm BIBP COVID-19 vaccine

Sinopharm BBIBP-CorV, also known as the Sinopharm COVID-19 vaccine,[8] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[9] BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19.[10]

Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed BBIBP-CorV 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).[11] In December 2020, the UAE previously announced interim results showing 86% efficacy.[12] While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.[13]

BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia,[14][15][16] Africa,[17][18][19] South America,[20][21][22] and Europe.[23][24][25] Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021.[26] On 7 May 2021, the World Health Organization approved the vaccine for emergency use[27] and Sinopharm later signed purchase agreements for 170 million doses from COVAX.[28]

The other inactivated virus COVID-19 vaccine developed by Sinopharm is WIBP-CorV.

See also[]

References[]

  1. ^ "中国医药集团有限公司主要领导调整" (in Chinese). Sinopharm.
  2. ^ "Liu Jingzhen". Bloomberg.
  3. ^ "中国医药集团总公司2016年度第一期超短期融资券发行披露材料" [Pospectus of 2016 (batch 1) Ultra-short-term financing of Sinopharm]. Sinopharm (in Chinese). Shanghai Clearing House. 19 January 2016. Retrieved 22 November 2016.
  4. ^ "2015 Annual Report" (PDF). China Traditional Chinese Medicine. Hong Kong Stock Exchange. 28 April 2016. Retrieved 22 November 2016.
  5. ^ "央企名录 (List of Central SOEs)". Official website of SASAC (in Chinese). Retrieved 3 March 2016.
  6. ^ http://beta.fortune.com/global500/sinopharm-205
  7. ^ "Chinese President Xi Jinping orders crackdown over 'appalling' vaccine scandal". South China Morning Post. 23 July 2018. Retrieved 29 November 2018.
  8. ^ How the Sinopharm Vaccine Works Jonathan Corum and Carl Zimmer 22 March 2021, www.nytimes.com, accessed 11 April 2021
  9. ^ Reuters Staff (2020-11-19). "China Sinopharm's coronavirus vaccine taken by about a million people in emergency use". Reuters. Retrieved 2020-12-09.
  10. ^ Corum, Jonathan; Zimmer, Carl (2021-04-26). "How the Sinopharm Vaccine Works". The New York Times. ISSN 0362-4331. Retrieved 2021-04-29.
  11. ^ Kaabi, Nawal Al; Zhang, Yuntao; Xia, Shengli; et al. (May 26, 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. 326 (1): 35–45. doi:10.1001/jama.2021.8565. PMC 8156175. PMID 34037666.
  12. ^ "UAE: Ministry of Health announces 86 per cent vaccine efficacy". gulfnews.com. Retrieved 2020-12-13.
  13. ^ "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg.com. 2020-12-09. Retrieved 2020-12-09.
  14. ^ Liu R (2020-12-31). "China gives its first COVID-19 vaccine approval to Sinopharm". Reuters. Retrieved 2020-12-31.
  15. ^ Turak, Natasha (2021-01-18). "The UAE is on track to have half its population vaccinated by the end of March". CNBC. Retrieved 2021-01-21.
  16. ^ Dawn.com (2021-02-02). "PM Imran kicks off Pakistan's Covid-19 vaccination drive". DAWN.COM. Retrieved 2021-02-03.
  17. ^ Reuters Staff (2021-01-24). "Sisi says Egypt to begin COVID-19 vaccinations on Sunday". Reuters. Retrieved 2021-01-24.
  18. ^ Dumpis, Toms (2021-01-27). "Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine". Morocco World News. Retrieved 2021-01-28.
  19. ^ "Zimbabwe starts administering China's Sinopharm vaccines". thestar.com. 2021-02-18. Retrieved 2021-02-20.
  20. ^ "Argentina autoriza la vacuna china Sinopharm para mayores de 60 años". El Comercio. Retrieved 2021-03-26.
  21. ^ Aquino, Marco (2021-02-10). "'The best shield': Peru launches inoculation drive with Sinopharm vaccine". Reuters. Retrieved 2021-02-10.
  22. ^ "Bolivia begins inoculation with Sinopharm jabs | The Star". www.thestar.com.my. Retrieved 2021-02-28.
  23. ^ "Serbia Becomes First European Nation To Use China's Sinopharm Vaccine". RadioFreeEurope/RadioLiberty. Retrieved 2021-01-21.
  24. ^ "Hungary first EU nation to use China's Sinopharm vaccine against COVID". euronews. 2021-02-24. Retrieved 2021-02-26.
  25. ^ "Belarus begins COVID-19 vaccinations with Chinese shots". eng.belta.by. 2021-03-15. Retrieved 2021-03-16.
  26. ^ "Which companies will likely produce the most COVID-19 vaccine in 2021?". Pharmaceutical Processing World. 2021-02-05. Retrieved 2021-02-28.
  27. ^ Taylor, Adam (7 May 2021). "WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine". The Washington Post. Retrieved 7 May 2021.
  28. ^ "Chinese drugmakers agree to supply more than half a billion vaccines to COVAX". Reuters. 2021-07-12. Retrieved 2021-07-13.

External links[]

Retrieved from ""